Relapse in High-Risk Neuroblastoma

Despite successfully completing a lengthy and aggressive standard-of-care regimen for high-risk neuroblastoma, relapse continues to present a significant risk to your child’s health.

  • Some data suggests about half of children will relapse
  • Rates of overall survival significantly worsen with relapse
  • When high-risk neuroblastoma does relapse, it’s usually within the first two years
  • By preventing a return to active disease, your child can avoid further exposure to aggressive medications

Maintenance therapy could offer an additional layer of protection against relapse

The addition of maintenance therapy after up-front treatment may help to improve your child’s treatment outcomes, prolong the period of remission, and increase overall survival rates.

Introducing IWILFIN

IWILFIN has been shown to reduce the risk of relapse by 52%

IWILFIN is a well-tolerated maintenance therapy used for lowering the risk of relapse in children with high-risk neuroblastoma. IWILFIN is prescribed once your child has achieved remission through completion of upfront treatment, such as chemotherapy and immunotherapy, and is conveniently taken at home.